Patients Undergoing Genetic Test for Uveal Melanoma Will Have Option to Store Remaining Tissue for Future Use
Castle Biosciences News Release 9/30/13 – Castle Biosciences Inc. announced today the availability of a tumor tissue repository for patients whose tumors are being tested with the Company’s gene test for uveal, or ocular, melanoma.… read more
In his first few weeks as head of the melanoma group at Memorial Sloan-Kettering Cancer Center seven years ago, a young man walked into Dr. Gary Schwartz’s office with a rare form of the skin cancer that affects the eye.
“It was horrible. He died of metastatic disease. He was only 24.… read more
In the online journal PLOS Currents: Evidence on Genomic Tests, the DecisionDx-UM molecular test was cited as the most accurate prognostic factor for individualizing care for uveal melanoma patients. “… the DecisionDx-UM gene expression profile test is a stand-alone platform which requires no other information for maximal prognostic accuracy and which circumvents many of the drawbacks of chromosomal methods…”
DecisionDx-UM groups patients into high- and low-risk categories and is being used to better determine follow-up care.… read more
If you’ve been diagnosed with uveal (ocular) melanoma, one of the most pressing questions is your prognosis, or odds of survival.
In up to 50% of uveal melanoma patients, the cancer may spread to the liver, where it is usually fatal. However, a new experimental treatment, meant to starve the liver tumor and help the body’s own immune system fight the cancer, may have the potential to impact survival.… read more
Dr. J. William Harbour is the ocular oncologist who developed DecisionDx-UM, the first and only validated prognostic test for uveal, or ocular, melanoma. The test predicts with a very high degree of accuracy which uveal tumors will likely spread–and thus ultimately prove fatal–and which will not, a valuable tool for guiding clinical treatment.… read more